Dr. Jim Wu is Founder, Chairman and CEO of Ark. He has over 26 years of experience in pharmaceutical research and development. Prior to founding the company, Dr. Wu served as a senior director of Roche R&D Center (China) Ltd., where he participated in multiple drug discovery programs in virology, oncology, and metabolic diseases. Dr. Wu is a prolific scientist with over 65 research papers published in international peer reviewed journals and is a co-inventor of ziresovir.
Dr. Wu obtained his PhD from Brown University and his bachelor's degree from University of Science and Technology of China. He was a post-doctoral fellow at Harvard Medical School and formerly served on the editorial board of Antimicrobial Agents and Chemotherapy, one of the major anti-infectious disease publications.
Dr. Haiqing Yuan is Chief Scientific Officer and Chief Operating Officer of Ark. Dr. Yuan has over 20 years of management and technical leadership experience in drug discovery and development. Prior to joining Ark, Dr. Yuan was a senior director at the international drug service unit of WuXi AppTec and, before then, a research investigator at Allergan, where he led multiple drug discovery programs. Dr. Yuan is an inventor and author of over 50 granted patents, research papers, and book chapters.
He obtained his PhD from Virginia Polytechnic Institute and State University and his bachelor's degree from Fudan University. Dr. Yuan performed post-doctoral research at University of Notre Dame and Walther Cancer Institute.
Mr. Yan Wu is Chief Medical Officer of Ark. Mr. Wu has over 30 years of experience and a proven record in clinical development. Mr. Wu was formerly a vice president at Hutchison MediPharma Co., Ltd. Prior to that, he held leadership roles at the clinical division of various global biopharmaceutical companies, including Biogen, Boehringer Ingelheim, Quintiles (now IQVIA), and AstraZeneca.
Mr. Wu obtained his bachelor's and master's degree from Shanghai Jiao Tong University School of Medicine.
Dr. John Zhang is Executive Vice President of Early Development and Project Management at Ark. Dr. Zhang has over 20 years of solid industry experience across a variety of therapeutic areas. Dr. Zhang was a vice president at Immune Pharmaceuticals Inc. He has served as a director and a clinical scientist of pharmacovigilance at Tesaro (now GSK). Prior to that, he also worked at Abbott Laboratories (now AbbVie). Dr. Zhang contributed to the successful development of blockbuster drugs in his industry career, such as Humira at Abbott Laboratories and Zejula at Tesaro.
Dr. Zhang obtained his PhD from Rutgers University, master's degree from University of California, Los Angeles. He is a certified toxicologist by The American Board of Toxicology.